Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans

Diabetologia

Volumn 45, Issue 10, 2002, Pages 1410-1415

  Vella, A ^a   Shah, P ^a   Reed, A ^a   Adkins, A ^a   Basu, R ^a   Rizza, R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cortisol secretion; Exendin 4; GLP 1; Glucose production; Insulin action

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLAMP; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME DEGRADATION; EVALUATION; GLUCOSE TRANSPORT; HUMAN; HYDROCORTISONE RELEASE; INSULIN RELEASE; NORMAL HUMAN; PRIORITY JOURNAL; STIMULATION;

ADULT; ANIMALS; ANTIGENS, CD26; BIOTRANSFORMATION; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; INSULIN; KINETICS; LIZARDS; PEPTIDE FRAGMENTS; PEPTIDES; REFERENCE VALUES; VENOMS;

EID: 0036035521     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0924-4     Document Type: Article

References (35)

1. Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagon like peptide I(7-37) actions on endocrine pancreas. Diabetes 38:338-342
2. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR (1997) Glucagon-like peptide-1 (GLP-1) a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536
3. Gutniak MK, Linde B, Holst JJ, Efendic S (1994) Subcutaneous injection of the incretin hormones glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044
4. Dupre J, Behme MT, Hramiak IM et al. (1995) Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630
5. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 47:159-169
6. Drucker DJ (1998) Glucagon-like peptides. Diabetes 47:159-169
7. Byrne MM, Goke B (1996) Human studies with glucagon-like-peptide-1 potential of the gut hormone for clinical use. Diabet Med 13:854-860
8. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682
9. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I (1994) Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37:1163-1166
10. Delgado E, Luque MA, Alcantara A et al. (1995) Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16:225-229
11. Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I (1993) Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 77:1654-1657
12. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J (1994) Glucagon-like peptide-1(7-36)amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: One of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135:2070-2075
13. Villanueva-Penacarrillo ML, Delgado E, Trapote MA et al. (1995) Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146:183-189
14. Morales M, Lopez-Delgado MI, Alcantara A et al. (1997) Preserved GLP-I effects on glycogen synthase alpha activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 46:1264-1269
15. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, Valverde I (1998) Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase alpha in hepatocytes from normal and diabetic rats. Endocrinology 139:2811-2817
16. Miki H, Namba M, Nishimura T et al. (1996) Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decrases intracellular cAMP content in isolated rat adipocytes. Biochim Biophys Acta 1312:132-136
17. Mizuno A, Kuwajima M, Ishida K et al. (1997) Extrapan-creatic action of truncated glucagon-like peptide-I in otsuka long-evans tokushima fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 46:745-749
18. Sandhu H, Wiesenthal SR, MacDonald PE et al. (1999) Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045-1053
19. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
20. Vella A, Shah P, Basu R et al. (2001) Effects of glucagon-like peptide-1-(7,36)-amide on initial splanchnic glucose uptake and insulin action in people with type 1 diabetes mellitus. Diabetes 50:565-572
21. Orskov L, Holst JJ, Moller J et al. (1996) GLP-1 does not acutely affect insulin sensitivity in healthy men. Diabetologia 39:1227-1232
22. Freyse EJ, Knospe S, Becher T, El Hag O, Goke B, Fischer U (1999) Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism 48:134-137
23. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA (2000) Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49:611-617
24. Toft-Nielsen M, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556
25. Edwards CM, Todd JF, Mahmoudi M et al. (1999) Gluca-gon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93
26. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405
27. Eng J, Andrews PC, Kleinman WA, Singh L, Raufman JP (1990) Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem 265:20259-20262
28. Greig NH, Holloway HW, De Ore KA et al. (1999) Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50
29. Edwards CM, Stanley SA, Davis R et al. (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161
30. Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA (1998) Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake. Diabetes 47:1735-1747
31. Rizza RA, Mandarino LJ, Gerich JE (1981) Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240:E630-E639
32. Steele R, Wall J, DeBodo R, Altszuler N (1956) Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24
33. Ryan AS, Egan JM, Habener JF, Elahi D (1998) Insulino-tropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2404
34. Larsson H, Holst JJ, Ahren B (1997) Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422
35. Dinneen S, Alzaid A, Miles J, Rizza R (1993) Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin Invest 92:2283-2290